LONDON, Sept 28 (Reuters) - A keenly awaited battle between GlaxoSmithKline and Merck & Co has begun in Europe, with the launch of Glaxo’s cervical cancer vaccine Cervarix -- a rival to Merck’s established Gardasil. Both products are touted as multibillion-dollar-a-year sellers and the looming marketing clash promises to be one of the most fiercely fought in the pharmaceutical industry.
